Wir sind mit live! Mehr erfahren

Psyence Biomedical

PBM

Börsenwert 16,1 Mio. $

4,22 USD

-0,10

2,31 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

4,44

+0,22

5,21 %

1 Tag

-2,31 %

5 Tage

-13,52 %

1 Monat

-27,49 %

3 Monate

40,2 %

6 Monate

-28,11 %

Seit Jahresbeginn

-15,43 %

1 Jahr

-80,43 %

5 Jahre

-99,95 %

10 Jahre

-99,95 %

Profil: Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Mitarbeiter: 12

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 0 %

Neutral 100 %

Negativ 0 %

Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine

Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program

Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Psyence BioMed Announces Strategic Ibogaine Investment

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD). Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.

Psyence BioMed Announces Strategic Ibogaine Investment

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine development Positioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangements Designed to coordinate supply, manufacturing, regulatory and potential clinical development activities through a single U.S. entity with U.S.-based partners NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd.

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development

Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built

Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) technologies, has been selected to support the administration of Scripius' commercial, Medicare, and Medicaid pharmacy benefit programs. Through this collaboration, Tredium will provide its claims platform to support accurate and reliable processing for Scripius and the customers it serves. Scripius empowers health plans, health systems, and self-funded employers to better manage rising pharmacy cos.

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Over the weekend, President Donald Trump issued an executive order aimed at speeding psychedelic drug reviews, while also backing faster ibogaine research with a reported $50 million commitment, helping ignite premarket buying across the space and lowering perceived regulatory risk for companies tied to psychedelic development.

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt